Takeda: Actos reduces risk of recurrent stroke in diabetic patients

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Takeda Pharmaceuticals North America, Inc. said the PROactive study showed that Actos (pioglitazone HCl), an oral anti-diabetic medication, reduced the risk of recurrent stroke to 5.6% from 10.2%, in patients with type 2 diabetes.

The randomized, double-blind study examined the effects of Actos on the risk of stroke and other cardiovascular outcomes in 5,238 high-risk patients with type 2 diabetes with and without prior stroke.

Takeda is a pharmaceutical company based in Lincolnshire, Ill.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.